Creative Biolabs Provides Various Antibody-drug Conjugates Linkers Modules

New York – February 27, 2019 – Creative Biolabs, an expert antibody company focusing on antibody-drug conjugates (ADC) development, now provides various ADC linker modules that can meet specific needs of global customers.

Consisting of a monoclonal antibody, a toxic payload and a chemical linker, antibody-drug conjugates (ADCs) combine the cytotoxic potency of a drug with the target specificity of an antibody. The successful ADCs are contingent on chemical linkers of >95% purity, which facilitate the conjugation of ADC toxins to antibodies and dictate the release mechanism of an ADC.

The ideal ADC linker is supposed to be stabilized in the systemic circulation and readily release the cytotoxic payload in its active form upon reaching the target site. On the whole, the types of linkers are categorized as cleavable and non-cleavable linkers. Cleavable linkers rely on the inherent properties of a cell’s cytoplasmic compartments for selective release of the cytotoxic drug, while noncleavable linkers depend on lysosomal proteolytic degradation of the antibody to release the drug molecule.

“Proper linker selection will not only ease the process of obtaining the conjugate but also help enhance the chemical and serum stability of the ADC. Cleavable linkers mainly include chemically cleavable linkers that respond to low pH (acid-labile linkers) or reducing environment (disulfide linkers), applied to the the early generations of ADCs, and the enzymatically cleavable linkers that are susceptible to the action of certain lysosomal enzymes (peptide linkers or β-glucuronide linkers), to achieve enhanced serum stability and reduced off-target toxicity,” introduced by a scientist in Creative Biolabs.

“Compared to cleavable linkers, noncleavable linkers are equipped with superior stability within circulation. However, these linkers are also more dependent on efficient internalization and intracellular degradation of the antibody for effective drug activation. As a result, ADCs with noncleavable linkers are restricted to the antigen-positive tumor cells. Therefore, a suitable ADC linker is selected in terms of different project needs and practical conditions.”

Based on the well-established “DrugLnk” organic synthesis platform, scientists in Creative Biolabs are capable of choosing the right antibody-drug linkage to optimize the therapeutic efficacy and tolerability of ADCs. More information on ADC development can be reached at

About Creative Biolabs

With more than a decade of exploration and expansion, Creative Biolabs provides current research and service capacity that covers the entire new drug discovery and development pipeline, ranging from early discovery, pre-clinical evaluations, cGMP manufacturing, to clinical trials. As an international cooperation, Creative Biolabs established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with customers and research partners to develop new medicines for a better, healthier world. After years of pursuit for perfection, Creative Biolabs has established leadership in targeted immunotherapy and antibody-drug conjugate (ADC) development. They offer customers comprehensive one-stop-shop of all aspects in ADC research and evaluation, ranging from antigen selection, antibody production/optimization, payload-linker synthesis, ADC conjugation, to various stages of ADC characterization and pre-clinical evaluation.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States